2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Leukemia, Myeloid, Acute
9
Leukemia
9
Hematologic Neoplasms
7
Lymphoma, Non-Hodgkin
6
Lymphoma
6
Multiple Myeloma
4
Primary Immunodeficiency Diseases
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Immunoproliferative Disorders
3
Immune System Diseases
3
Hodgkin Disease
3
Cytopenia
3
Anemia, Aplastic
3
Thalassemia
2
Osteopetrosis
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hemoglobinopathies
2
Fanconi Anemia
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Anemia, Sickle Cell
2
Anemia, Diamond-Blackfan
2
Anemia
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thymoma
1
Interventions
Rituximab
10
Valganciclovir
6
Etoposide
4
Doxorubicin
4
Valacyclovir
3
Gemcitabine
3
Dexamethasone
3
Cyclophosphamide
3
Cisplatin
3
spartalizumab
2
pembrolizumab
2
pegaspargase
2
Zidovudine
2
Vincristine
2
Radiotherapy, Intensity-Modulated
2
Prednisone
2
Methylprednisolone
2
Methotrexate
2
Matrix-M
2
Leucovorin
2
Lenalidomide
2
Cell Count
2
Carboplatin
2
Blood Specimen Collection
2
Acyclovir
2
valomaciclovir
1
toripalimab
1
threonic acid
1
ruxolitinib
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Epstein-Barr Virus Infections
×
AP 1903 reagent
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled